English

Hyaluronic Acid Dermal Filler

MONALISA

GENOSS
For Patients & Doctors

Korean Pop Artist, Eon Lee

Beautiful Smile Again

Beautiful Smile Forever

SOFT

Frown lines

MILD

Perioral lines
Cheek volume
Forehead lines

HARD

Nose
Nasolabial folds
Chin & facial oval

ULTRA

Nasal augmentation
Chin & facial oval


MILD
SOFT
HARD
ULTRA
MILD
HARD
HARD / ULTRA

MONALISA

1. Volume Effect and Retention

The uniform sized hyaluronic acid particles with optimal viscoelasticity can maintain a long-lasting volume.

2. Safe to Use on Patients

MONALISA is safe to use on patients due to low level of endotoxin and essentially no BDDE residue.

3. Easy Procedural Operation

The ergonomically-designed rod and grip allow the even distribution of pressure during injection to enable an accurate and safe treatment for both the clinician and the patient.

4. Highly Pure Hyaluronic Acid

GENOSS implements a strict quality control system through direct involvement in the entire production process from the base material of hyaluronic acid to the final product.

5. Global Standard Quality Control

To guarantee the quality of MONALISA, GENOSS strictly fulfills and complies with the international quality regulations, including KGMP, ISO 13485 and ISO 9001.

Hyaluronic acid dermal filler

MONALISA

MONALISA provides superior volume effect and maintains high performance for long lasting durability

CE
2195

Product	SOFT	MILD	HARD
REF	HAF10S27T	HAF10M27T	HAF10H27T
Appearance	No impurities, transparent and colorless gel		
Composition	Cross-linked hyaluronic acid		
Concentration	20 mg/mL		
Particle Size	200 μm	400 μm	600 μm
Syringe Volume	1.0 mL		
Recommended Indication	Superficial dermis	Superficial dermis / Middle layer of subcutis	Middle to deep layer of subcutis
Needle Size*	27G TW (2ea)	27G TW (2ea)	27G TW (2ea)
Storage	2~25℃		

* Needle size is subject to change without notice.

Hyaluronic acid dermal filler with Lidocaine

MONALISA *Lidocaine*

MONALISA Lidocaine Filler has been developed by adding MONALISA with a local anesthetic lidocaine to lessen pain during an operation.

Product	SOFT	MILD	HARD	ULTRA
REF	MPF10S	MPF10M	MPF10H	MPF10U
Appearance	No impurities, transparent and colorless gel			
Composition	Cross-linked hyaluronic acid			
Concentration	24 mg/mL			
Lidocaine	0.3 %			
Particle Size	200 μm	400 μm	600 μm	900 μm
Syringe Volume	1.0 mL			
Recommended Indication	Superficial dermis	Superficial dermis / Middle layer of subcutis	Middle to deep layer of subcutis	Deep to very deep layer of subcutis
Needle Size*	30G TW (2ea)	27G TW (2ea)	25G TW , 27G TW	25 G TW , 27G TW
Storage	2~25℃			

* Needle size is subject to change without notice.

Thin - wall Needle

Thin-wall Needle enables smooth injection which reduces patient's discomfort during the procedure



MONALISA Lidocaine

- 30G TW needle for Soft, Mild type
- 27G TW needle for Hard, Ultra type

MONALISA

- 27G TW needle for Soft, Mild, Hard type

Ergonomic Design

Ergonomically-designed grips enable an accurate, convenient and safe treatment.

Design



Grip



An ergonomically designed hand-grip that comfortably fits in user's hands and enables injection into various parts of the face.

Safe to Use on Patients

The risk of allergic reaction, edema and other adverse side effects were minimized by significantly reducing the BDDE (chemical agent used to cross-link hyaluronic acid) to the point where it is undetectable.

MONALISA Performance Test

Genoss Research Institute

	Standard	Result
Appearance	No impurities, transparent and colorless gel	Pass
Content	18 ~ 22 mg	20.1 mg
pH	6.5 ~7.5	7.18
BDDE Residues	< 2 ppm	**Not Detected**
Heavy Metal	< 10 ppm	Pass
Volume	> 1.0 mL	Pass

MONALISA Lidocaine Performance Test

		Standard	Result
Appearance		No impurities, transparent and colorless gel	Pass
Content	**Hyaluronic acid**	21.6 ~ 26.4 mg	24.1 mg
	Lidocaine	0.27 ~ 0.33 %	0.31 %
pH		6.5 ~7.5	7.19
BDDE Residues		< 2 ppm	**Not Detected**
Heavy Metal		< 10 ppm	Pass
Volume		> 1.0 mL	Pass

* What is BDDE? 1,4-butanediol diglycidyl ether (BDDE) is a chemical cross-linking agent that produces hyaluronic acid into a gel form. The BDDE residue should not exceed 2 ppm. In the MONALISA, the BDDE residue was undetectable.

Volume Maintenance

Hy-BRID technology enables the production of highly dense and uniform particles in MONALISA. The volume is maintained for at least 6 months before the dissolution process begins.

Uniform particle size and dissolution rate



1 Injection of the MONALISA into the treatment site.

2 MONALISA has uniform particle size which yields a volume of natural feel.

3 MONALISA maintains the same dissolution rate and it is gradually and naturally dissolved and discharged from the body.

Viscoelasticity with the Optimal Ratio

The application of the Hy-BRID technology allows the MONALISA to achieve the ideal viscoelasticity for greater volume and durability compared to current competitors.

Elasticity



Viscosity



▲ MONALISA ■ Competitor

*** Hy-BRID Technology**

Hyper Cross-linked
Based on non-animal HA
Residue-free
Improved **D**ensity and elasticity



Highly Pure Hyaluronic Acid

GENOSS implements a strict quality control system through direct involvement in the entire production process from the base material of hyaluronic acid to the final product.

Production Process of Hyaluronic Acid

Cultivation → Fermentation / Extraction → Purification → **Hyaluronic Acid**

Clinical Cases

Case 1

Before | After



Case 2

Before | After



Case 3

Before | After

Case 4

Before | After



COMPANY INFORMATION:

Since its establishment in 2004, GENOSS began its endeavor to become the world's leading medical device company. The primary mission set forth by GENOSS is to focus on delivering treatment solutions and promoting the well-being of its consumers and patients.

Due to the size-controlled filler particles with optimal viscoelasticity, MONALISA offers superior volumizing effect with long-lasting results. Ergonomically-designed grips enable an accurate, convenient and safe treatment.

MONALISA, HA dermal filler is one of the beauty treatment solutions offered by GENOSS Company. Hyaluronic acid, the raw material of MONALISA is produced in the GENOSS GMP facility, where it is strictly controlled to produce API grade materials. Through a triple-check quality control and manufacturing system, GENOSS is able to take the raw material and convert it into a final product of superior value.

To guarantee the quality of MONALISA, GENOSS strictly fulfills and complies with the international quality regulations, including KGMP, ISO 13485 and ISO 9001. Furthermore, the CE mark No.1293 on MONALISA confirms its conformity with all of the legal requirements.

MONALISA is made of the highest quality base materials manufactured by the most advanced manufacturing process in strictly managed GMP facilities.

MONALISA



GENOSS Co., Ltd.
HEAD OFFICE / MANUFACTURER
1F, Gyeonggi R&DB Center, 105 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16229, Korea
Tel. +82-31-888-5100, **Fax.** +82-31-888-5105

www.genoss.com
www.monalisafiller.com

CAT-MO.K(Rev.4, 1809)